Michael Lee Brooks Sells 1,002 Shares of Syneos Health, Inc. (NASDAQ:SYNH) Stock

Syneos Health, Inc. (NASDAQ:SYNHGet Rating) COO Michael Lee Brooks sold 1,002 shares of the firm’s stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $78.00, for a total value of $78,156.00. Following the completion of the sale, the chief operating officer now directly owns 47,552 shares of the company’s stock, valued at approximately $3,709,056. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Lee Brooks also recently made the following trade(s):

  • On Thursday, July 21st, Michael Lee Brooks sold 1,002 shares of Syneos Health stock. The stock was sold at an average price of $76.00, for a total value of $76,152.00.
  • On Tuesday, July 19th, Michael Lee Brooks sold 1,002 shares of Syneos Health stock. The stock was sold at an average price of $74.00, for a total value of $74,148.00.

Syneos Health Stock Performance

Shares of NASDAQ SYNH opened at $79.14 on Friday. The firm’s 50-day moving average price is $71.79 and its 200-day moving average price is $77.22. Syneos Health, Inc. has a 52-week low of $62.28 and a 52-week high of $104.18. The company has a market cap of $8.12 billion, a PE ratio of 34.26 and a beta of 1.70. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.89.

Syneos Health (NASDAQ:SYNHGet Rating) last announced its quarterly earnings results on Friday, April 29th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.05. Syneos Health had a net margin of 4.54% and a return on equity of 13.33%. The firm had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the business posted $0.66 earnings per share. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. As a group, analysts anticipate that Syneos Health, Inc. will post 4.63 EPS for the current year.

Institutional Trading of Syneos Health

Large investors have recently made changes to their positions in the stock. Signaturefd LLC grew its stake in shares of Syneos Health by 328.6% in the fourth quarter. Signaturefd LLC now owns 240 shares of the company’s stock worth $25,000 after acquiring an additional 184 shares during the period. Jackson Grant Investment Advisers Inc. bought a new stake in shares of Syneos Health in the first quarter worth approximately $26,000. Independence Bank of Kentucky bought a new stake in shares of Syneos Health in the first quarter worth approximately $28,000. CWM LLC grew its stake in shares of Syneos Health by 124.7% in the second quarter. CWM LLC now owns 418 shares of the company’s stock worth $30,000 after acquiring an additional 232 shares during the period. Finally, First Horizon Advisors Inc. grew its stake in shares of Syneos Health by 59.6% in the fourth quarter. First Horizon Advisors Inc. now owns 391 shares of the company’s stock worth $39,000 after acquiring an additional 146 shares during the period. 98.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SYNH has been the subject of several recent research reports. Guggenheim initiated coverage on Syneos Health in a research report on Monday, May 23rd. They set a “buy” rating and a $81.00 price objective for the company. TheStreet lowered Syneos Health from a “b” rating to a “c+” rating in a research report on Wednesday, May 18th. Deutsche Bank Aktiengesellschaft initiated coverage on Syneos Health in a research report on Monday, April 11th. They set a “buy” rating and a $102.00 price objective for the company. Jefferies Financial Group lowered Syneos Health from a “buy” rating to a “hold” rating and lowered their price objective for the company from $101.00 to $75.00 in a research report on Monday, April 25th. Finally, Mizuho reissued a “buy” rating and set a $94.00 price objective on shares of Syneos Health in a research report on Friday, May 20th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Syneos Health presently has an average rating of “Moderate Buy” and an average price target of $97.11.

About Syneos Health

(Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Read More

Insider Buying and Selling by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.